Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Custeau

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Cancer Chemotherapy and Pharmacology|April 26, 2001
Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activityH Gourdeau, L Bibeau, F Ouellet, et al.
Molecular Cancer Therapeutics|December 7, 2002
The pro-apoptotic protein, Bik, exhibits potent antitumor activity that is dependent on its BH3 domainY Tong, Q Yang, C Vater, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Cancer Chemotherapy and Pharmacology|April 26, 2001
Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activityH Gourdeau, L Bibeau, F Ouellet, et al.
Molecular Cancer Therapeutics|December 7, 2002
The pro-apoptotic protein, Bik, exhibits potent antitumor activity that is dependent on its BH3 domainY Tong, Q Yang, C Vater, et al.
Pageof 1